kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Human CD155 / PVR Protein, Mouse IgG2a Fc Tag, low endotoxin , 100µg  

Recombinant Human CD155 / PVR Protein, Mouse IgG2a Fc Tag, low endotoxin , 100µg

Recombinant Human CD155 / PVR Protein, Trp 21 - Asn 343, expressed from human 293 cells (HEK293), mouse IgG2a Fc Tag, low endotoxin

recombinant, human, protein, PVR, FLJ25946, PVS, CD155, TAGE4, HVED, NECL5

More details


Availability: within 7 days

455,00 €

CD155 is a Type I transmembrane glycoprotein in the immunoglobulin superfamily. Commonly known as Poliovirus Receptor (PVR) due to its involvement in the cellular poliovirus infection in primates, CD155's normal cellular function is in the establishment of intercellular adherens junctions between epithelial cells.
CD155/PVR was originally isolated based on its ability to mediate polio virus attachment to host cells. The fulllength (or CD155 alpha isoform) is synthesized as a 417 amino acid (aa) precursor that contains a 20 aa signal sequence, a 323 aa extracellular region, a 24 aa TM segment and a 50 aa cytoplasmic tail. The extracellular region contains one N terminal V type and two C2 type Ig like domains.
CD155 is a transmembrane protein with 3 extracellular immunoglobulin-like domains, D1-D3, where D1 is recognized by the virus. Low resolution structures of CD155 complexed with poliovirus have been obtained using electron microscopy while a high resolution structures of theectodomain D1 and D2 of CD155 were solved by x-ray crystallography.

Recombinant Human CD155, Mouse IgG2a Fc Tag, low endotoxin (CD5-H5254) is expressed from human 293 cells (HEK293). It contains AA Trp 21 - Asn 343 (Accession # NP_006496.4).
Predicted N-terminus: Trp 21

Molecular Characterization
This protein carries a mouse IgG2a Fc tag at the C-terminus.
The protein has a calculated MW of 62.2 kDa. As a result of glycosylation, the protein migrates as 70-100 kDa under reducing (R) condition, and 130-160 kDa under non-reducing (NR) condition (SDS-PAGE).

Less than 0.1 EU per μg by the LAL method.

>95% as determined by SDS-PAGE.

Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor"
Zhao, Dong, Deng et al
Oncoimmunology (2023) 12 (1), 2265703
(2) "Intensified NK cell therapy in combination with low-dose chemoradiotherapy against human colorectal cancer"
Nguyen, Bae, Park et al
Cancer Immunol Immunother (2023)
(3) "Renal tubular epithelial cells are constitutive non-cognate stimulators of resident T cells"
Sadasivam, Jie, Hamad
Cell Rep (2023) 42 (10), 113210
Showing 1-3 of 520 papers.